13Aug 2024
Qdenga Dengue Vaccine Shows 50% Efficacy, Promising Long-Lasting Protection

Qdenga Dengue Vaccine Shows 50% Efficacy, Promising Long-Lasting Protection

The dengue vaccine Qdenga, pre-approved by the WHO, has demonstrated over 50% efficacy in reducing cases, with lasting protective effects and a strong safety profile. A global review of 19 studies involving 20,000 participants found that over 90% of recipients developed immunity against all four dengue virus serotypes. The vaccine, developed by Takeda Pharmaceutical, holds promise as a key tool in dengue prevention, especially in endemic regions.

  • #general surgery
  • #pharmacology
  • #general medicine
  • #psych
  • #rheumatology
  • #pathology
  • #radiology
  • #anaesthesia
  • #psychiatry
  • #fmt
  • #emergency medicine
  • #academics
  • #nursing
  • #pharmacy
  • #trichology
  • #andrology
  • #orthopaedics
  • #critical care
  • #dermatology
  • #dentistry
  • #oncology
  • #business
  • #gastroenterology
  • #nephrology
  • #diagnostics
  • #urology
  • #ophthalmology
  • #gynaecology - ivf
  • #pediatrics
  • #neurology
  • #ent
  • #pulmonology
  • #family health
  • #cardiology
  • #endo-diabetology

Like

Save

Share